RALEIGH, N.C., Sept. 8, 2011 /PRNewswire/ -- Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the appointment of Nader Naeymi-Rad as Chief Executive Officer. Mr. Naeymi-Rad, formerly Chief Operating Officer, succeeds John Campbell, who co-founded the firm more than 14 years ago.
John Campbell and Ann Campbell, who will transition from her current role as President, will co-lead a committee of the Campbell Alliance Board of Directors that will focus on strategic growth opportunities in the US and abroad.
"Ann and I have decided to take on new roles at the firm in order to completely focus on accelerating its growth. Campbell Alliance has always been a high-performance, growth-oriented firm. In our 14 years of operation, we have averaged 25% year-over-year growth in revenue. We've reached a point in the firm's evolution where maintaining this level of growth will require a combination of organic growth in our core business and external opportunities — possibly in the form of strategic acquisitions," stated Mr. Campbell.
Campbell Alliance was acquired by inVentiv Health in February 2011 and operates as inVentiv Health's Consulting segment. Paul Meister, Chief Executive Officer of inVentiv Health, stated, "From the very beginning we knew Campbell Alliance was a strong leader in pharmaceutical and biotech consulting. The firm has an outstanding reputation, proven consulting capabilities, and a strong track record of growth. As the anchor of our consulting segment, the Campbell Alliance team is adding significant value to our broader business in ways that have exceeded our expectations. We fully support these positive management changes, have great confidence in Nader and his new management team, and very much look forward to working with John and Ann in their new roles."
Ms. Campbell added, "Today, as an inVentiv Health company, we have access to tremendous resources — on a global scale — to make our accelerated growth plan a reality. With Nader in place we are well positioned to pursue an aggressive growth plan — focused on external opportunities — knowing that our core business is in good hands."
As CEO, Mr. Naeymi-Rad will look to aggressively grow Campbell Alliance with a continued focus on the foundational characteristics that have helped the firm advance to this point: unmatched client satisfaction, deep functional expertise, and proven consulting methodologies.
"I'd like to extend my sincere thanks to John, Ann, and the entire Campbell Alliance team for their confidence in me. I've had the honor of building this firm from the ground up, and I look forward to taking it to the next level," stated Mr. Naeymi-Rad.
Mr. Naeymi-Rad joined the firm shortly after its founding in 1997. Since that time he has played a pivotal role in the growth of the firm. He led the development of the Brand Management Practice from its inception to become the firm's largest practice area, as well as the development of new service lines, including the Launch Playbook™ (launch planning and execution) and Innovation2Value™ (commercial planning). Mr. Naeymi-Rad helped launch and co-lead the firm's Business Development Practice and spearheaded the development of the firm's operations in Europe. In his most recent role as Chief Operating Officer, he successfully implemented the firm's regional operating model, which resulted in increased profitability and helped deepen relationships with key pharmaceutical and biotech clients at the local level.
Campbell Alliance also announced executive promotions and organizational changes today in a separate press release.
About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced acquisitions, and any additional leverage we may incur in connection with the financing thereof, on the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; the impact of any default by any of our credit providers or swap counterparties; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability accurately forecast insurance claims within our self-insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses, including the acquisitions of i3 Global and PharmaNet Development Group, Inc., into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; and the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Director, Public and Media Relations
919-844-7100, extension 7195
SOURCE Campbell Alliance